FDA Public Hearing Today on Potential CBD Regulation

The agency is hosting a public hearing on May 31 to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including cannabidiol.

The Food and Drug Administration is hosting a public hearing on May 31 to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including cannabidiol. The public hearing will be held from 8 a.m. to 6 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, in Silver Spring, Md.

FDA had announced the hearing on April 2, saying it would also accept electronic or written comments until July 2, 2019. Visit www.regulations.gov and search for docket number FDA-2019-N-1482 to file a comment.

The agency also formed an internal agency working group to explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed, including consideration of what statutory or regulatory changes might be needed and what the public health impact of that marketing would be.

Bulwark FR Quiz

OH&S Digital Edition

  • OHS Magazine Digital Edition - September 2020

    September 2020

    Featuring:

    • WINTER HAZARDS
      Winter Hazards Preparation Should Kick Off in the Fall Months
    • OIL & GAS
      How Safety Has Become a Priority for the Oil Sector
    • COMBUSTIBLE DUST
      Protecting the Plant from Catastrophic Combustible Dust Explosions
    • FACILITY SAFETY
      Empowering Workers in an Uncertain World
    View This Issue